Fate Therapeutics, founded by Rudolf Jaenisch, began its first in-human Phase 1 clinical trial, treating its first patient with FT596, a natural killer cell-based cancer immunotherapy engineered using the company’s induced pluripotent stem cell (iPSC) platform. They also announced a collaboration with Janssen Biotech, Inc. to further develop additional off-the-shelf iPSC-derived cell-based immunotherapies.